Cohance Lifesciences (COHANCE) Stock Overview
Engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
COHANCE Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cohance Lifesciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹438.00 |
| 52 Week High | ₹917.85 |
| 52 Week Low | ₹266.70 |
| Beta | 0.61 |
| 1 Month Change | -5.40% |
| 3 Month Change | 8.08% |
| 1 Year Change | -51.84% |
| 3 Year Change | -17.34% |
| 5 Year Change | -18.96% |
| Change since IPO | 159.90% |
Recent News & Updates
Recent updates
Narrative Update • Aug 06
COHANCE: Leadership Turnover And Governance Changes Will Pressure Future Returns
The analyst fair value estimate for Cohance Lifesciences has moved from ₹300.00 to ₹341.00, with analysts linking this change to updated assumptions on revenue growth, profit margin, future P/E multiples, and a slightly lower discount rate. What's in the News A board meeting of Cohance Lifesciences is scheduled for Aug 05, 2026 at 15:30 Indian Standard Time to consider and approve unaudited financial results for the quarter ended 30 June 2026, source: company board meeting notice.
Narrative Update • Jul 17
COHANCE: Leadership Transition And EPS Repricing Will Drive Future Upside
The updated analyst price target for Cohance Lifesciences has shifted from a fair value estimate of ₹1,111.73 to ₹987.40 as analysts adjust their assumptions on revenue growth, profit margin and future P/E expectations. What's in the News for Cohance Lifesciences Appointment of Umang Vohra as Group CEO from May 20, 2026, with former leader Mr. Sharma continuing as Advisor for nine months to support the transition.Narrative Update • Jul 03
COHANCE: Leadership Turnover And Lower Margin Outlook Will Pressure Future Returns
Analysts have cut their price target fair value for Cohance Lifesciences from ₹640 to ₹300, citing updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Cohance Lifesciences scheduled a board meeting on April 27, 2026 to take note of the resignation of the Executive Chairman and Director, consider the appointment of Umang Vohra as Additional Director and Chairman and Group Chief Executive Officer, and review the Cohance Lifesciences Limited Employee Stock Option Plan, 2026.
Narrative Update • Jun 18
COHANCE: Leadership Transition And Incentive Plans Will Support Complex Pharma Expansion
Analysts have kept their price target for Cohance Lifesciences steady at ₹516.78, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margins and future P/E expectations. What’s in the News for Cohance Lifesciences Appointment of Umang Vohra as Group CEO of Cohance Lifesciences, effective May 20, 2026, with the outgoing leader, Mr. Sharma, continuing as an advisor for around nine months to support the transition.Narrative Update • Jun 04
COHANCE: Leadership Transition Into Complex Pharma Platforms Will Shape Future Potential
Analysts have lifted their price target for Cohance Lifesciences from ₹477.67 to ₹516.78, reflecting updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Board meeting scheduled for May 12, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to review policies on material event determination and disclosures under SEBI listing regulations.Analysis Article • May 15
Cohance Lifesciences Limited Just Missed Earnings - But Analysts Have Updated Their Models
Cohance Lifesciences Limited ( NSE:COHANCE ) shareholders are probably feeling a little disappointed, since its shares...Narrative Update • May 04
COHANCE: Leadership Transition And FDA Compliance Response Will Shape Future Potential
Analysts have trimmed their fair value estimate for Cohance Lifesciences from about ₹507 to about ₹478 as they fine tune assumptions around revenue growth, profit margins and the future P/E multiple. What's in the News Board meeting scheduled for April 27, 2026, at 7:00 a.m. IST to review leadership changes, including taking note of the resignation of the Executive Chairman and Director.Narrative Update • Apr 20
COHANCE: FDA Compliance Progress Will Support Future Upside Potential
Analysts have kept their price target for Cohance Lifesciences steady at around ₹507, with only minor tweaks to inputs like revenue growth, profit margin and forward P/E contributing to this unchanged view. What's in the News The U.S. FDA issued Warning Letter No. 718812 to Cohance Lifesciences Limited regarding significant CGMP violations at its finished pharmaceuticals facility in Medchal Malkajgiri, Telangana (U.S. FDA).Narrative Update • Apr 06
COHANCE: FDA Warning Letter Remediation Will Support Future Upside Potential
Analysts have trimmed their fair value estimate for Cohance Lifesciences from about ₹512.67 to roughly ₹507.11, reflecting updated assumptions around revenue growth, profit margins and future P/E expectations. What’s in the News The U.S. FDA has issued Warning Letter No. 718812 to Cohance Lifesciences Limited regarding Current Good Manufacturing Practice (CGMP) violations at its Nacharam facility in Medchal Malkajgiri, Telangana, India (FDA / CDER).Narrative Update • Mar 22
COHANCE: FDA Compliance Remediation Will Support Confidence In Future Prospects
Analysts have kept their fair value estimate for Cohance Lifesciences steady at ₹512.67 per share, reflecting unchanged assumptions on discount rate, revenue growth, profit margin, and future P/E despite the latest review of their price target framework. What's in the News The U.S. Food and Drug Administration issued Warning Letter No. 718812 to Cohance Lifesciences Limited, citing significant violations of Current Good Manufacturing Practice regulations at its drug manufacturing facility in Medchal Malkajgiri, Telangana, India (Regulatory Authority, FDA).Narrative Update • Mar 07
COHANCE: FDA Warning Letter Remediation Will Support Confidence In Future Prospects
Analysts have maintained their price target for Cohance Lifesciences at ₹512.67, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E in their latest update. What's in the News The U.S. FDA issued Warning Letter No. 718812 to Cohance Lifesciences Limited following an inspection of its drug manufacturing facility in Medchal Malkajgiri in August 2025, citing significant violations of CGMP regulations for finished pharmaceuticals, including inadequate investigations into drug quality issues and weaknesses in cleaning validation and equipment maintenance (Regulatory Authority, FDA CDER).Narrative Update • Feb 20
COHANCE: FDA Compliance Remediation Will Support Confidence In Long Term Growth
Analysts have revised their fair value estimate for Cohance Lifesciences from about ₹733 to roughly ₹513, reflecting updated assumptions around slightly higher revenue growth, a lower projected profit margin, and a reduced future P/E multiple. What's in the News The U.S. FDA issued Warning Letter No. 718812 to Cohance Lifesciences regarding CGMP violations at its drug manufacturing facility in Medchal Malkajgiri, citing concerns around investigations of quality issues, cleaning validation, and cross contamination risks (Regulatory Authority – Enforcement Actions).Analysis Article • Feb 16
Cohance Lifesciences Limited (NSE:COHANCE) Analysts Are Reducing Their Forecasts For Next Year
The latest analyst coverage could presage a bad day for Cohance Lifesciences Limited ( NSE:COHANCE ), with the analysts...Analysis Article • Feb 08
Is Cohance Lifesciences (NSE:COHANCE) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative Update • Feb 05
COHANCE: Leadership Shift And US Investment Will Drive 2030 Revenue Ambition
Analysts have nudged their price target for Cohance Lifesciences to ₹733.33, with the modest shift linked to slightly refined assumptions around the discount rate and future P/E, while keeping fair value estimates broadly consistent. What's in the News Board meeting scheduled for February 12, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ending December 31, 2025 (company filing).Narrative Update • Jan 22
COHANCE: Leadership Shift And US Investment Will Support 2030 Revenue Ambition
Analysts have trimmed their fair value estimate for Cohance Lifesciences from ₹801.11 to ₹733.33, as they now factor in slightly lower revenue growth, a softer profit margin profile, and a modestly reduced future P/E assumption. What's in the News A board meeting is scheduled for February 12, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ending December 31, 2025 (company filing).Analysis Article • Jan 21
Cohance Lifesciences Limited (NSE:COHANCE) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless
To the annoyance of some shareholders, Cohance Lifesciences Limited ( NSE:COHANCE ) shares are down a considerable 26...Narrative Update • Jan 06
COHANCE: Leadership Change And US Funding Will Support 2030 Revenue Ambition
Analysts have trimmed their price target on Cohance Lifesciences to ₹801.11 per share, citing updated assumptions for long term revenue growth, profit margins and future P/E multiples that leave their fair value view essentially unchanged. What's in the News Board meeting scheduled on February 12, 2026, to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ending December 31, 2025 (company filing).Narrative Update • Dec 15
COHANCE: Leadership Transition And US Subsidiary Funding Will Support Ambitious 2030 Revenue Goal
Analysts have maintained their price target for Cohance Lifesciences at ₹801.11, citing only marginal tweaks to revenue growth and profit margin assumptions that were not sufficient to change their overall valuation framework. What's in the News The board will consider up to USD 10 million fund infusion into US subsidiary NJ Bio Inc through compulsorily convertible preferred stock at the December 2, 2025 meeting (company filing) Management reiterates its long-term ambition with revenue guidance targeting USD 1 billion (about INR 85 billion) by 2030 (company guidance) The board has approved the resignation of Managing Director Dr V Prasada Raju, effective October 28, 2025, with an ongoing advisory role to support the leadership transition (board resolution) A board meeting is scheduled on November 12, 2025 to review and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, along with the related press release (company notice) Valuation Changes Fair Value: Unchanged at ₹801.11 per share, indicating no revision to the core valuation outcome.Narrative Update • Dec 01
COHANCE: Future Leadership Transition Will Strengthen Long-Term Revenue Ambitions
Analysts have revised their fair value estimate for Cohance Lifesciences downward from ₹930 to ₹801.11, citing slightly reduced expectations for revenue growth and profit margin projections. What's in the News Cohance Lifesciences has provided revenue guidance for 2030, with a target of USD 1 billion (INR 85 billion) in revenue.Analysis Article • Nov 20
Cohance Lifesciences' (NSE:COHANCE) Sluggish Earnings Might Be Just The Beginning Of Its Problems
The market wasn't impressed with the soft earnings from Cohance Lifesciences Limited ( NSE:COHANCE ) recently. We did...Narrative Update • Nov 17
COHANCE: Future Leadership Transition Will Drive Renewed Momentum
Analysts have revised their price target for Cohance Lifesciences downward from ₹1,170.63 to ₹930.00. This change reflects updated expectations for lower profit margins and slightly reduced revenue growth projections.Analysis Article • Nov 14
What Does The Future Hold For Cohance Lifesciences Limited (NSE:COHANCE)? These Analysts Have Been Cutting Their Estimates
One thing we could say about the analysts on Cohance Lifesciences Limited ( NSE:COHANCE ) - they aren't optimistic...Narrative Update • Nov 02
COHANCE: New Facility Expansions Will Drive Future Opportunity And Margins
Narrative Update on Cohance Lifesciences: Analyst Price Target Revision Analysts have maintained their fair value estimate for Cohance Lifesciences at ₹1,170.63 per share. They cite stable future growth expectations and unchanged profit margin forecasts.Analysis Article • Oct 28
Market Participants Recognise Cohance Lifesciences Limited's (NSE:COHANCE) Revenues
Cohance Lifesciences Limited's ( NSE:COHANCE ) price-to-sales (or "P/S") ratio of 25.8x may look like a poor investment...Narrative Update • Oct 18
New Acquisitions Will Expand Opportunities In ADCs And Oligonucleotides
Analysts have revised their price target for Cohance Lifesciences down from ₹1,213 to ₹1,171. This change reflects tempered expectations for revenue growth, partially offset by stronger profit margins.Narrative Update • Aug 30
New Acquisitions Will Expand Opportunities In ADCs And Oligonucleotides
Cohance Lifesciences’ consensus analyst price target saw a modest decrease to ₹1213, as both net profit margin and future P/E remained virtually unchanged, indicating stable fundamentals despite the downward revision in fair value. What's in the News Cohance Lifesciences invested USD 10 million to expand cGMP bioconjugation capabilities at its U.S. subsidiary, NJ Bio, enhancing its Antibody-Drug Conjugate (ADC) offering and supporting global innovators from early development to late-phase clinical supply.Narrative Update • Aug 16
New Acquisitions Will Expand Opportunities In ADCs And Oligonucleotides
The consensus analyst price target for Cohance Lifesciences has been revised downward, primarily reflecting a notable decline in net profit margin and a higher future P/E multiple, resulting in a new target of ₹1246. What's in the News Board meeting scheduled to consider and approve unaudited financial results for the quarter ending June 30, 2025.
New Narrative • Feb 23
Converting Increased RFPs Into Contracts Will Strengthen Future Prospects
Strategic acquisitions and diversification into niche markets enhance Suven's revenue potential and improve margins through high-value offerings.Analysis Article • Dec 15
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Aug 03
Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)
Suven Pharmaceuticals Limited's ( NSE:SUVENPHAR ) robust recent earnings didn't do much to move the stock. However the...Shareholder Returns
| COHANCE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.5% | 0.5% | -0.3% |
| 1Y | -51.8% | 14.0% | -3.0% |
Return vs Industry: COHANCE underperformed the Indian Pharmaceuticals industry which returned 14% over the past year.
Return vs Market: COHANCE underperformed the Indian Market which returned -3% over the past year.
Price Volatility
| COHANCE volatility | |
|---|---|
| COHANCE Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in IN Market | 8.9% |
| 10% least volatile stocks in IN Market | 3.4% |
Stable Share Price: COHANCE has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: COHANCE's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 1,212 | Umang Vohra | www.cohance.com |
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms (FDE); packaging and clinical trial support services; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies.
Cohance Lifesciences Limited Fundamentals Summary
| COHANCE fundamental statistics | |
|---|---|
| Market cap | ₹167.56b |
| Earnings (TTM) | ₹1.06b |
| Revenue (TTM) | ₹21.42b |
157.7x
P/E Ratio7.8x
P/S RatioIs COHANCE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COHANCE income statement (TTM) | |
|---|---|
| Revenue | ₹21.42b |
| Cost of Revenue | ₹6.35b |
| Gross Profit | ₹15.07b |
| Other Expenses | ₹14.01b |
| Earnings | ₹1.06b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.78 |
| Gross Margin | 70.36% |
| Net Profit Margin | 4.96% |
| Debt/Equity Ratio | 9.9% |
How did COHANCE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/20 05:39 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cohance Lifesciences Limited is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Harith Ahamed | Avendus Spark |
| Vijayaraghavan Swaminathan | Avendus Spark |